Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
Zhengyang Hao, Yanzhou Zhang Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of ChinaCorrespondence: Yanzhou Zhang, Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Repub...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-07-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/dapagliflozin-and-empagliflozin-in-heart-failure-with-reduced-ejection-peer-reviewed-fulltext-article-IJGM |
| _version_ | 1818242832769482752 |
|---|---|
| author | Hao Z Zhang Y |
| author_facet | Hao Z Zhang Y |
| author_sort | Hao Z |
| collection | DOAJ |
| description | Zhengyang Hao, Yanzhou Zhang Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of ChinaCorrespondence: Yanzhou Zhang, Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China, Email zhangyanzhou666@outlook.comObjective: Dapagliflozin 10 mg and empagliflozin 10 mg have been recommended to treat heart failure with reduced ejection fraction (HFrEF), and the purpose of this study was to compare the efficacy and safety of them in HFrEF.Methods: Two hundred and thirty-three patients with HFrEF admitted to a tertiary hospital of Zhengzhou and commenced to take dapagliflozin 10 mg/d or empagliflozin 10 mg/d were retrospectively included and separated into the dapagliflozin group (n=105) and the empagliflozin group (n=128). Their cardiac function indices before and after therapy were compared, together with the ratios of adverse events during therapy.Results: After 6 months of therapy, left ventricular ejection fraction was higher, and the ratio of New York Heart Association functional class III or IV, left ventricular end-diastolic diameter, and N-terminal pro-B-type natriuretic peptide were lower in the empagliflozin group than the dapagliflozin group (P< 0.05). During 6 months of therapy, there were no statistically significant differences for the ratios of hypotension, deteriorating kidney function, and genitourinary infections between the dapagliflozin and empagliflozin groups (P> 0.05).Conclusion: Despite its many limitations, this study suggested that different SGLT2 inhibitors might have differences regarding efficacy in HFrEF. We look forward to future studies to verify our conjectures.Keywords: dapagliflozin, empagliflozin, heart failure with reduced ejection fraction |
| first_indexed | 2024-12-12T13:51:30Z |
| format | Article |
| id | doaj.art-95b9bbc222444e0ba99e7204c2a4f78c |
| institution | Directory Open Access Journal |
| issn | 1178-7074 |
| language | English |
| last_indexed | 2024-12-12T13:51:30Z |
| publishDate | 2022-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj.art-95b9bbc222444e0ba99e7204c2a4f78c2022-12-22T00:22:34ZengDove Medical PressInternational Journal of General Medicine1178-70742022-07-01Volume 155915591876289Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective StudyHao ZZhang YZhengyang Hao, Yanzhou Zhang Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of ChinaCorrespondence: Yanzhou Zhang, Department of Cardiology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, People’s Republic of China, Email zhangyanzhou666@outlook.comObjective: Dapagliflozin 10 mg and empagliflozin 10 mg have been recommended to treat heart failure with reduced ejection fraction (HFrEF), and the purpose of this study was to compare the efficacy and safety of them in HFrEF.Methods: Two hundred and thirty-three patients with HFrEF admitted to a tertiary hospital of Zhengzhou and commenced to take dapagliflozin 10 mg/d or empagliflozin 10 mg/d were retrospectively included and separated into the dapagliflozin group (n=105) and the empagliflozin group (n=128). Their cardiac function indices before and after therapy were compared, together with the ratios of adverse events during therapy.Results: After 6 months of therapy, left ventricular ejection fraction was higher, and the ratio of New York Heart Association functional class III or IV, left ventricular end-diastolic diameter, and N-terminal pro-B-type natriuretic peptide were lower in the empagliflozin group than the dapagliflozin group (P< 0.05). During 6 months of therapy, there were no statistically significant differences for the ratios of hypotension, deteriorating kidney function, and genitourinary infections between the dapagliflozin and empagliflozin groups (P> 0.05).Conclusion: Despite its many limitations, this study suggested that different SGLT2 inhibitors might have differences regarding efficacy in HFrEF. We look forward to future studies to verify our conjectures.Keywords: dapagliflozin, empagliflozin, heart failure with reduced ejection fractionhttps://www.dovepress.com/dapagliflozin-and-empagliflozin-in-heart-failure-with-reduced-ejection-peer-reviewed-fulltext-article-IJGMdapagliflozinempagliflozinheart failure with reduced ejection fraction |
| spellingShingle | Hao Z Zhang Y Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study International Journal of General Medicine dapagliflozin empagliflozin heart failure with reduced ejection fraction |
| title | Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study |
| title_full | Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study |
| title_fullStr | Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study |
| title_full_unstemmed | Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study |
| title_short | Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study |
| title_sort | dapagliflozin and empagliflozin in heart failure with reduced ejection fraction a retrospective study |
| topic | dapagliflozin empagliflozin heart failure with reduced ejection fraction |
| url | https://www.dovepress.com/dapagliflozin-and-empagliflozin-in-heart-failure-with-reduced-ejection-peer-reviewed-fulltext-article-IJGM |
| work_keys_str_mv | AT haoz dapagliflozinandempagliflozininheartfailurewithreducedejectionfractionaretrospectivestudy AT zhangy dapagliflozinandempagliflozininheartfailurewithreducedejectionfractionaretrospectivestudy |